Skip to main content
Top

07-11-2017 | Premixed insulins | Review | Article

Use of 50/50 Premixed Insulin Analogs in Type 2 Diabetes: Systematic Review and Clinical Recommendations

Journal: Diabetes Therapy

Authors: Gary Deed, Gary Kilov, Trisha Dunning, Richard Cutfield, Jane Overland, Ted Wu

Publisher: Springer Healthcare

Abstract

Introduction

Premixed insulin analogs represent an alternative to basal or basal–bolus insulin regimens for the treatment of type 2 diabetes (T2D). “Low-mix” formulations with a low rapid-acting to long-acting analog ratio (e.g., 25/75) are commonly used, but 50/50 formulations (Mix50) may be more appropriate for some patients. We conducted a systematic literature review to assess the efficacy and safety of Mix50, compared with low-mix, basal, or basal–bolus therapy, for insulin initiation and intensification.

Methods

MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, ClinicalTrials.gov, LillyTrials.com, and NovoNordisk-trials.com were searched (11 or 13 Dec 2016) using terms for T2D, premixed insulin analogs, and/or Mix50. Studies (randomized, nonrandomized, or observational; English only) comparing Mix50 with other insulins (except human) and reporting key efficacy [glycated hemoglobin (HbA1c), fasting and postprandial glucose] and/or safety (hypoglycemia, weight gain) outcomes were eligible for inclusion. Narrative reviews, letters, editorials, and conference abstracts were excluded. Risk of bias in randomized trials was assessed using the Cochrane tool.

Results

MEDLINE and EMBASE searches identified 716 unique studies, of which 32 met inclusion criteria. An additional three studies were identified in the other databases. All 19 randomized trials except one were open label; risk of other biases was generally low. Although not conclusive, the evidence suggests that Mix50 may provide better glycemic control (HbA1c reduction) and, particularly, postprandial glucose reduction in certain patients, such as those with high carbohydrate diets and Asian patients, than low-mix and basal therapy. Based on this evidence and our experience, we provide clinical guidance on factors to consider when deciding whether Mix50 is appropriate for individual patients.

Conclusions

Mix50 may be more suitable than low-mix therapy for certain patients. Clinicians should consider not only efficacy and safety but also patient characteristics and preferences when tailoring insulin treatment to individuals with T2D.

Funding

Eli Lilly.
Literature
1.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Suppl 1):S64–74.CrossRef
2.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 executive summary. Endocr Pract. 2016;22:84–113.CrossRefPubMed
3.
Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—Clinical Practice Guidelines for developing a diabetes mellitus comprehensive care plan—2015—executive summary. Endocr Pract. 2015;21:413–37.
4.
International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1–52.CrossRef
5.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.CrossRefPubMed
6.
The Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2016–2018. East Melbourne: RACGP; 2016.
7.
Unnikrishnan AG, Tibaldi J, Hadley-Brown M, et al. Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. Int J Clin Pract. 2009;63:1571–7.CrossRefPubMedPubMedCentral
8.
Wu T, Betty B, Downie M, et al. Practical guidance on the use of premix insulin analogs in initiating, intensifying, or switching insulin regimens in type 2 diabetes. Diabetes Ther. 2015;6:273–87.CrossRefPubMedPubMedCentral
9.
Brito M, Ligthelm RJ, Boemi M, et al. Intensifying existing premix therapy (BIAsp 30) with BIAsp 50 and BIAsp 70: a consensus statement. Indian J Endocrinol Metab. 2011;15:152–60.CrossRefPubMedPubMedCentral
10.
Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127:S25–38.CrossRefPubMed
11.
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentral
12.
Ilag LL, Kerr L, Malone JK, Tan MH. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther. 2007;29:1254–70.CrossRef
13.
Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med. 2008;149:549–59.CrossRefPubMedPubMedCentral
14.
Chen W, Qian L, Watada H, et al. Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: subgroup analysis of the comparison between low mixed insulin and mid mixed insulin as starter insulin for patients with type 2 diabetes mellitus (CLASSIFY study) randomized trial. J Diabetes Investig. 2017;8:75–83.
15.
Cucinotta D, Smirnova O, Christiansen JS, et al. Three different premixed combinations of biphasic insulin aspart—comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab. 2009;11:700–8.CrossRefPubMed
16.
Domeki N, Matsumura M, Monden T, Nakatani Y, Aso Y. A randomized trial of step-up treatment with premixed insulin lispro-50/50 vs aspart-70/30 in patients with type 2 diabetes mellitus. Diabetes Ther. 2014;5:403–13.CrossRefPubMedPubMedCentral
17.
Farcasiu E, Ivanyi T, Mozejko-Pastewka B, et al. Efficacy and safety of prandial premixed therapy using insulin lispro mix 50/50 3 times daily compared with progressive titration of insulin lispro mix 75/25 or biphasic insulin aspart 70/30 twice daily in patients with type 2 diabetes mellitus: a randomized, 16-week, open-label study. Clin Ther. 2011;33:1682–93.CrossRefPubMed
18.
Giugliano D, Tracz M, Shah S, et al. Initiation and gradual intensification of premixed insulin lispro therapy versus basal ± mealtime insulin in patients with type 2 diabetes eating light breakfasts. Diabetes Care. 2014;37:372–80.CrossRefPubMed
19.
Jacober SJ, Scism-Bacon JL, Zagar AJ, et al. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab. 2006;8:448–55.CrossRefPubMed
20.
Jain SM, Mao X, Escalante-Pulido M, Vorokhobina N, Lopez I, Ilag LL. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab. 2010;12:967–75.CrossRefPubMedPubMedCentral
21.
Jia W, Xiao X, Ji Q, et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal–bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. Lancet Diabetes Endocrinol. 2015;3:162–254.CrossRef
22.
Kazda C, Hulstrunk H, Helsberg K, Langer F, Forst T, Hanefeld M. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complicat. 2006;20:145–52.CrossRefPubMed
23.
Miser WF, Arakaki R, Jiang H, Scism-Bacon J, Anderson PW, Fahrbach JL. Randomized, open-label, parallel-group evaluations of basal–bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther. 2010;32:896–908.CrossRefPubMed
24.
Novo Nordisk. Effect of biphasic insulin aspart 50 compared to biphasic insulin aspart 30 both in combination with metformin in Chinese subjects with type 2 diabetes. http://​www.​novonordisk-trials.​com/​WebSite/​search/​TrialDetail.​aspx?​Command=​GetTrialDetail&​TrialId=​BIASP-1858&​Index=​8. Accessed 13 Dec 2016.
25.
Roach P, Arora V, Campaigne BN, Mattoo V, Rangwala S, India Mix25/Mix50 Study Group. Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab. 2003;5:311–6.CrossRefPubMed
26.
Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2007;29:2349–64.CrossRefPubMed
27.
Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008;31:20–5.CrossRefPubMed
28.
Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther. 2006;28:1649–57.CrossRefPubMed
29.
Su Q, Liu C, Zheng H, et al. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): subgroup analysis of a phase 4 open-label randomized trial. J Diabetes. 2017;9:575–85. doi:10.​1111/​1753-0407.​12442.
30.
Suzuki K, Morikawa H, Iwanaga M, Aizawa Y. Investigation of the introduction of three times daily injections of Insulin Lispro Mixture-50 on an outpatient basis: therapeutic effects of 12 months’ treatment with and without concomitant sulfonylurea. J Diabetes. 2012;4:262–3.CrossRefPubMedPubMedCentral
31.
Watada H, Su Q, Li PF, Iwamoto N, Qian L, Yang WY. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open-label, randomized trial (CLASSIFY study). Diabetes Metab Res Rev. 2017;33:e2816.CrossRef
32.
Zafar MI, Ai X, Shafqat RA, Gao F. Effectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetes. Ther Clin Risk Manag. 2015;11:27–32.
33.
Davidson JA, Lacaya LB, Jiang H, et al. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract. 2010;16:818–28.CrossRefPubMed
34.
Hirsch IB, Yuan H, Campaigne BN, Tan MH. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocr Pract. 2009;15:343–8.CrossRefPubMed
35.
Akahori H. Clinical evaluation of thrice-daily lispro 50/50 versus twice-daily aspart 70/30 on blood glucose fluctuation and postprandial hyperglycemia in patients with type 2 diabetes mellitus. Diabetol Int. 2015;6:275–83.CrossRef
36.
Ito H, Abe M, Antoku S, et al. Effects of switching from prandial premixed insulin therapy to basal plus two times bolus insulin therapy on glycemic control and quality of life in patients with type 2 diabetes mellitus. Drug Des Devel Ther. 2014;8:391–6.CrossRefPubMedPubMedCentral
37.
Mashitani T, Tsujii S, Hayashino Y, et al. Diurnal patterns of plasma glucose in patients with type 2 diabetes receiving sulfonylurea and effectiveness of once daily lispro mix 50/50 injections. Diabetol Int. 2014;5:30–5.CrossRef
38.
Nakashima E, Kuribayashi N, Ishida K, Taketsuna M, Takeuchi M, Imaoka T. Efficacy and safety of stepwise introduction of insulin lispro mix 50 in Japanese patients with type 2 diabetes inadequately controlled by oral therapy. Endocr J. 2013;60:763–72.CrossRefPubMed
39.
Novo Nordisk. Observational study of NovoMix® 50 for treatment of type 2 diabetics for 12 months. http://​www.​novonordisk-trials.​com/​WebSite/​search/​TrialDetail.​aspx?​Command=​GetTrialDetail&​TrialId=​BIASP-3674&​Index=​0. Accessed 13 Dec 2016.
40.
Novo Nordisk. Observational study on safety and efficacy of biphasic insulin aspart in type 2 diabetes patients. http://​www.​novonordisk-trials.​com/​WebSite/​search/​TrialDetail.​aspx?​Command=​GetTrialDetail&​TrialId=​BIASP-3669&​Index=​0 Accessed 13 Dec 2016.
41.
Shimizu H, Monden T, Matsumura M, Domeki N, Kasai K. Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients. Yonsei Med J. 2010;51:845–9.CrossRefPubMedPubMedCentral
42.
Tanaka M, Ishii H. Pre-mixed rapid-acting insulin 50/50 analogue twice daily is useful not only for controlling post-prandial blood glucose, but also for stabilizing the diurnal variation of blood glucose levels: switching from pre-mixed insulin 70/30 or 75/25 to pre-mixed insulin 50/50. J Int Med Res. 2010;38:674–80.CrossRefPubMed
43.
Tanaka M, Ishii H. Improvement in bedtime plasma glucose level serves as a predictor of long-term blood glucose control in patients with type 2 diabetes: a study with monotherapy of 50/50 premixed insulin analogue three times daily injection. J Diabetes Complicat. 2011;25:83–9.CrossRefPubMed
44.
Yamashiro K, Ikeda F, Fujitani Y, Watada H, Kawamori R, Hirose T. Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes. J Diabetes Investig. 2010;1:149–53.PubMedPubMedCentral
45.
Cho KY, Nakagaki O, Miyoshi H, Akikawa K, Astumi T. Evaluation of thrice-daily injections of insulin Lispro Mix 50/50 versus basal–bolus therapy in perioperative patients with type 2 diabetes. Diabetol Int. 2014;5:117–21.CrossRef
46.
Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32:1007–13.CrossRefPubMedPubMedCentral
47.
Goh S-Y, Hussein Z, Rudijanto A. Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries. J Diabetes Investig. 2017;8:635–45. doi:10.​1111/​jdi.​12647.
48.
Kataoka M, Venn BJ, Williams SM, Te Morenga LA, Heemels IM, Mann JI. Glycaemic responses to glucose and rice in people of Chinese and European ethnicity. Diabet Med. 2013;30:e101–7.CrossRefPubMed
49.
Møller JB, Dalla Man C, Overgaard RV, et al. Ethnic differences in insulin sensitivity, β-cell function, and hepatic extraction between Japanese and Caucasians: a minimal model analysis. J Clin Endocrinol Metab. 2014;99:4273–80.CrossRefPubMed
50.
Pathan MF, Sahay RK, Zargar AH, et al. South Asian Consensus Guideline: use of insulin in diabetes during Ramadan. Indian J Endocrinol Metab. 2012;16:499–502.CrossRefPubMedPubMedCentral
51.
Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38:2354–69.CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »